Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.69
+0.02 (+2.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $433000.00 · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
10.4x
↓ROE
59.5%
↑Gross Margin
43.4%
↓Debt/Equity
-2.54
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.6%
FCF CAGR
—
FCF margin
0.2%
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $262.9M · net income $-68.6M · FCF $433000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $262.9M | $262.9M | $257.5M | $269.4M | $284.3M |
| Net Income | $-68.6M | $-68.6M | $-48.8M | $-65.1M | $-202.3M |
| EBITDA | $38.7M | $38.7M | $50.7M | $30.3M | $-121.7M |
| EPS | -0.35 | -0.35 | -0.25 | -0.33 | -1.44 |
| Gross Margin | 43.4% | 43.4% | 45.9% | 43.1% | 33.6% |
| Operating Margin | 0.8% | 0.8% | 3.5% | 1.5% | -21.3% |
| Net Margin | -26.1% | -26.1% | -18.9% | -24.2% | -71.2% |
| Balance Sheet | |||||
| Debt/Equity | -2.54 | -2.54 | -5.40 | -47.95 | 6.79 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $433000.00 | $433000.00 | $16.9M | $-14.1M | $-78.3M |
| Returns | |||||
| ROE | 59.5% | 59.5% | 97.1% | 1044.6% | -427.9% |
| Valuation | |||||
| EV/EBITDA | 10.44 | 10.44 | 6.69 | 14.32 | — |
| P/B | — | — | — | — | 4.23 |
| Growth & Yield | |||||
| Revenue Growth | 2.1% | 2.1% | -4.4% | -5.2% | — |
| EPS Growth | -40.0% | -40.0% | 24.2% | 77.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+72.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.25 → -0.35
Residual
+72.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.